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The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and
chemoprophylaxis. The combination of atovaquone-proguanil (MalaroneW) has shown high efficacy against
Plasmodium falciparum with only mild side-effects. Treatment failures have been attributed to suboptimal dosages
or to parasite resistance resulting from a point mutation in the cytochrome b gene. In this paper, a case of early
treatment failure was reported in a patient treated with atovaquone-proguanil; this failure was not associated with a
mutation in the parasite cytochrome b gene, with impaired drug bioavailability, or with re-infection.
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Increasing reports of drug-resistant Plasmodium falciparum
throughout the world have forced changes in both
prevention and treatment. Atovaquone-proguanil (A-P,
MalaroneW, GlaxoSmithKline Inc) is one of the common
first-line agent for the prophylaxis [1-3] and treatment
[2,4,5] of falciparum malaria in France and causes only
mild side-effects. Since the introduction of the A-P com-
bination, several cases of treatment failure have been
observed in travellers returning from Africa [6-14]. Treat-
ment failures have been attributed to suboptimal dos-
age or impaired bioavailability, re-infection or to a
point mutation in the cytochrome b gene (pfcytb)
[4,9,15]. In this paper, a case of A-P treatment failure
in a military employee stationed in the Republic of
Ivory Coast was reported; this treatment failure was* Correspondence: nathalie_wurtz@yahoo.fr
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medium, provided the original work is propernot due to low plasma levels of the drug, mutations
in the pfcytb gene, or re-infection.
Case presentation
The patient was a 45-year-old military employee
deployed to Abidjan in the Republic of Ivory Coast (Port
Bouet camp). He had been stationed in Abidjan for six
months and had repeatedly forgotten to take the pre-
scribed anti-malarial chemoprophylaxis drug, doxycycline.
He presented general malaise and headaches on 27
September, 2011, and was treated by self-medication with
paracetamol. Two days later (29 September, 2011 (day 0)),
the patient consulted the medical centre of the camp,
where he presented headache, myalgias, chills and fever
with a temperature of 39.7°C. A blood smear examination
revealed P. falciparum at a parasitaemia of 0.74%, and a
rapid diagnosis test confirmed Plasmodium infection. The
patient was hospitalized and immediately treated with the
standard treatment of MalaroneW, four 250 mg tablets
daily on day 0, day 1 and day 2, associated with paraceta-
mol and the continuation of chemoprophylaxis with doxy-
cycline. The tablets were taken with fatty food and weretd. This is an Open Access article distributed under the terms of the Creative Commons
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ly cited.
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hospitalization. At day 1, the patient was asymptomatic
and afebrile. At day 2, after the last intake of MalaroneW,
the patient experienced a febrile peak at 38.5°C and blood
smear examination revealed a parasitaemia of 1.3%. Be-
cause of the recrudescent parasitaemia and according to
WHO guidelines for the assessment and monitoring of
anti-malarial drug efficacy for the treatment of uncom-
plicated falciparum malaria [16], the possibility of early
A-P treatment failure was considered, and the patient
was treated with 625 mg of quinine base (QuinimaxW)
orally three times daily for seven days, doxycycline
(100 mg twice daily for seven days) and paracetamol.
On 4 October (day 5), the parasitaemia decreased to
0.02%, and on 7 October (day 8), a QBC test was
negative.
Methods
Whole blood specimens from the first (day 0) and second
(day 2) episodes of malaria were submitted to the reference
laboratory for gene amplification by polymerase chain reac-
tion (PCR), sequencing, genetic analysis and quantification
of the plasma concentrations of drugs. No in vitro assays of
the P. falciparum isolates could be performed. The DNA
of both samples was extracted from blood samples using
the QIAamp DNA Mini Kit according to the manufac-
turer’s recommendations (Qiagen, France). Confirmation
of P. falciparum mono-infection was performed by real-
time LightCyclerW PCR (Roche, Meylan, France), as
described elsewhere [17]. The pfcytb and dihydrofolate
reductase (pfdhfr) genes were amplified by PCR and
sequenced for both isolates to detect mutations asso-
ciated with resistance to A-P, respectively, as described
[15,18,19]. Molecular markers of resistance [19], such
as pfcrt (chloroquine resistance transporter), pfmdr1
(multidrug resistance 1 protein), pfnhe1 (Na+/H+ ex-
porter 1), pfdhps (dihydropteroate synthetase), pftetQ
(tetQ family GTPase) and pfmdt (metabolite/drug trans-
porter) were also assessed. The single-nucleotide poly-
morphism and copy number assays for these different
genes were performed as previously described [15,20-
22]. The parasite diversity between day 0 and day 2 was
determined by genotyping the TRAP, 7A11, C4M79,
Pf2802, and Pf2689 microsatellite loci; the highly poly-
morphic loci of the merozoite surface protein 1 and 2
antigen genes (msp1-msp2); and the highly polymorphic
loci of the glutamate-rich protein gene (glurp) using
fluorescent end-labelled nested PCR and restriction
fragment length polymorphism analysis. The primer
sequences, PCR conditions, and genotyping methods
have been described elsewhere [23-25]. The drug ab-
sorption and compliance were estimated by quantifica-
tion of the drug levels in the patient’s plasma; these
assays were performed using a Waters Acquity UPLCinstrument (Milford, MA, USA). Separation was carried out
on an Acquity BEH C8 column (50 mm×2.1 mm, 1.7 μm)
maintained at 40°C. The mobile phase consisted of solvent
A (0.5% acetic acid in purified water) and solvent B (aceto-
nitrile). Two gradient programmes were used, one for the
quantification of proguanil, cycloguanil and doxycycline and
the second for the quantification of atovaquone. The flow
rate was 0.8 mL/min. The injection volume and total run
time were, respectively, 5 μL and 3 min. A purification step
was performed before analysis using i) an OASISW HLB
SPE cartridge (Waters, Milford, MA, USA) for progua-
nil, cycloguanil and doxycycline and ii) protein precipi-
tation by the addition of two volumes of an ACN/H2O/
acetic acid solution (85:14:1, v/v/v).
Consent
Informed consent was not required because the sampling
procedures and testing are part of the French national
recommendations for the care and surveillance of malaria.
Results
As previously observed on the blood smear, P. falciparum
is the only species detected by real-time PCR. The whole
sequencing of the pfcytb gene, which encodes the target of
atovaquone, revealed a wild-type P. falciparum isolate on
day 0 and day 2 (M133, Y268). Moreover, no other point
mutation was identified in the pfcytb gene. Genotyping of
the whole pfdhfr gene showed that the three of the five
major mutations (A16, N51I, C59R, S108N, I164) asso-
ciated with proguanil (cycloguanil)/ pyrimethamine resist-
ance were found in isolates from day 0 and day 2.
Genotyping of the pfcrt gene (wild type, K76), the pfmdr1
gene (N86, Y184F, S1034, N1042 and D1246) and the
pfdhps gene (S436A, A437G, K540, A581, and A613)
showed identical alleles. Only one copy each of pfmdr1,
pftetQ and pfmdt was found in each sample. The pfnhe1
microsatellite ms4760 exhibited profile 22 with one
DNNND repeat and two DDDNHNDNHNN repeats.
Genotyping of the parasites from days 0 and 2 using the
microsatellite loci, msp1, msp2, and glurp showed that the
alleles were identical for each locus in the two samples.
Ultra high-performance liquid chromatography was
performed on a blood sample withdrawn just before the
third MalaroneW administration. Thus, the results
showed the residual levels of drugs just before the last
intake. The atovaquone plasma concentration was
5.1 μg/mL, and the proguanil and doxycycline levels
were, respectively, equal to 380 ng/mL and 509 ng/mL.
The plasma concentration of cycloguanil was not deter-
mined due to the presence of an interfering signal.
Conclusion
MalaroneW, a fixed-dose combination of A-P, is highly ef-
fective for the treatment and prophylaxis of multi-drug-
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due to its convenient mode of administration (oral), short
treatment course (three days) and limited side effects. Ato-
vaquone, a ubiquinone analogue that binds to CYTB of
plasmodial mitochondria, exerts its action by inhibiting
electron transfer in the respiratory chain [26,27]. The pro-
guanil metabolite cycloguanil acts by inhibiting the para-
site PfDHFR protein, which is involved in pyrimidine
biosynthesis, and the addition of proguanil leads to an en-
hancement of atovaquone’s activity and reduces the chance
of mutations arising in the mitochondrial DNA of the mal-
aria parasite [28,29]. Since the introduction of the A-P
combination, few cases of treatment failure have been
identified in travellers returning from Africa [6-14]. Treat-
ment failures have been generally attributed to suboptimal
dosage, re-infections with a new parasite, or to a point mu-
tation (Y268N, Y268S or Y268C) in the pfcytb gene
[4,9,14,18]. However, several cases of clinical treatment
failure were not associated with any known pfcytb muta-
tion, the plasma drug concentrations were well within
curative range, and re-infection was excluded [7,8,13]. In
this paper, a case of early A-P treatment failure not asso-
ciated with pfcytb mutations in a military employee sta-
tioned in Abidjan in the Republic of Ivory Coast was
reported.
The residual drug levels were quantified on a sample
withdrawn between 23 to 24 hours after the second
MalaroneW intake. No recommended therapeutic con-
centrations are available for the A-P. Association and
data are missing especially in the treatment of uncompli-
cated falciparum imported malaria in Caucasians. How-
ever, regarding pharmacokinetics parameters of the both
drugs, and more particularly the elimination half-life, the
maximum concentrations and steady-state concentra-
tions, impaired bioavailability can be excluded [30-33].
Data about the relationship between plasma doxycycline
concentration and time in the same population are also
lacking. However, drug plasmatic level is in the same
other as that expected [34,35].
For further analysis, the day 0 and day 2 P. falciparum
isolates were investigated for point mutations in the
pfcytb codon 268 [15], and this analysis revealed wild-type
alleles in both isolates. Genotyping of the blood samples
from day 0 and day 2 at microsatellite loci (TRAP, 7A11,
C4M79, Pf2802, and Pf2689) and at the highly polymorphic
loci of the msp1 and msp2 antigen genes and of the glurp
gene were performed. The results showed that the two
samples had the same molecular signature and complete
homology, excluding the possibility of a re-infection, and
these results were confirmed by genotypic analysis of resist-
ance markers. Based on these results, the clinical and para-
sitological features of the patient between day 0 and day 2,
and the WHO definition of treatment failure [16,36], this
case could be classified as an early treatment failure.Several other factors may also contribute to the emer-
gence of A-P resistance, including hyperparasitaemia,
rapid metabolism of proguanil or prior exposure to
related drugs [37]. In this case, high parasitaemia was
not observed (parasitaemia on day 0 = 0.74%; parasit-
aemia on day 2 = 1.3%). Caucasians are known to
metabolize proguanil to cycloguanil relatively rapidly
compared to other ethnic groups, leaving the parasites
exposed to atovaquone alone for a longer period of time
[31]. However, there was no clear evidence to implicate
this mechanism as a factor in the emergence of A-P
resistance in this case. Moreover, the metabolic status
(i.e. poor/extensive) of the patient can’t be assumed
with this only concentration versus time level. In the
context of this case report, the genotype or an individ-
ual pharmacokinetics for proguanil was not possible.
In summary, this case represents the first observation
of the clinical failure of A-P treatment for P. falciparum
infection in a military in Ivory Coast that was not due to
impaired drug bioavailability, resistance due to pfcytb
mutations or re-infection with a new parasite. The absence
of mutations in pfcytb suggests that alternative mechanisms
may be involved in the resistance to this drug combination
[7,8]. Indeed, resistance may be associated with either in-
hibition or alteration of key enzymes that are targets for
anti-malarial drugs, or alteration of drug accumulation in
the parasite that results from reduced uptake of the drug,
increased efflux, or a combination of both processes [19].
Although clinical failure of A-P treatment is rare among
travellers, increased vigilance is required during treatment
and post-treatment, and the monitoring of the parasite
population should be strengthened. Further research is
required to gain a better understanding of the mechanisms
involved in the clinical failure observed after treatment with
MalaroneW, one of the few available drugs used to treat
infections with multidrug-resistant P. falciparum parasites.
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